OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
May 10, 2024
At CPHI NA, Rachel Harris, AstraZeneca, spoke on her work at BioPhorum to enable industry consensus and action for sustainability with drug delivery devices.
May 09, 2024
The company’s presentation at ASGCT includes preliminary data results for a child who received the gene therapy.
A greater understanding of molecular and cellular biology and technological advancements are revolutionizing the field of biologics.
May 08, 2024
The company is presenting preclinical data at the American Society of Gene & Cell Therapy annual meeting that supports the potential of the company’s CAP-002 gene therapy for correcting neurological phenotypes associated with genetic epilepsy due to syntaxin-binding protein 1 (STXBP1) mutations.
May 07, 2024
Novel delivery technologies enhance brain penetration to target neurodegenerative diseases and glioblastomas.
The two companies will combine their cell therapy platforms to develop convertibleCAR programs targeting solid tumors.
May 06, 2024
The use of appropriate taste-masking and appearance technologies can facilitate patient compliance.
May 05, 2024
A comparison between polysorbates and HPβCD determines the better stabilizer for biologics formulation.
May 03, 2024
In this exclusive Drug Digest video interview, Chris Spivey, Director, Industry Relations and Strategic Partnerships, talks with industry experts about various aspects of drug product stability testing.
May 02, 2024
In the new draft guidance, FDA provides recommendations on cell safety testing of human-sourced allogeneic cells for sponsor companies.